![Kathleen Glaub](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Kathleen Glaub
Directeur Général chez
CuraSen Therapeutics, Inc.
Fortune : - $ au 31/05/2026
Profil
Ms. Kathleen S.
Glaub is a Chief Executive Officer at CuraSen Therapeutics, Inc. She is on the Board of Directors at IO Biotech ApS.
Ms. Glaub was previously employed as an Independent Director by Aligos Therapeutics, Inc., a Chairman by Escient Pharmaceuticals, Inc., an Independent Director by IO Biotech, Inc., an Independent Director by Codexis, Inc., a Chief Executive Officer & Director by Afferent Pharmaceuticals, Inc., a President by Plexxikon, Inc., a Chief Financial Officer & Senior Vice President by Cell Genesys, Inc., a Treasurer by Genentech, Inc., and a Principal by Intel Corp.
She received her undergraduate degree from the University of California, Berkeley and an MBA from Kellogg School of Management.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
IO BIOTECH, INC. -.--% | 05/06/2025 | 0 ( -.--% ) | - $ | 31/05/2026 |
Postes actifs de Kathleen Glaub
| Sociétés | Poste | Début |
|---|---|---|
IO Biotech ApS
 IO Biotech ApS BiotechnologyHealth Technology Develops disruptive immune therapies | Directeur/Membre du Conseil | 11/06/2018 |
CuraSen Therapeutics, Inc.
 CuraSen Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company that develops novel treatments for psychiatric and neurodegenerative diseases | Directeur Général | 15/10/2024 |
Anciens postes connus de Kathleen Glaub
| Sociétés | Poste | Fin |
|---|---|---|
| IO BIOTECH, INC. | Directeur/Membre du Conseil | 31/03/2026 |
| CODEXIS, INC. | Directeur/Membre du Conseil | 30/09/2019 |
Afferent Pharmaceuticals, Inc.
 Afferent Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops novel, selective drugs for the treatment of a range of debilitating neurogenic disorders | Directeur Général | 01/07/2016 |
Plexxikon, Inc.
 Plexxikon, Inc. Miscellaneous Commercial ServicesCommercial Services Provides clinical and medical drug discovery and development services | President | 01/05/2013 |
| ALIGOS THERAPEUTICS, INC. | Directeur/Membre du Conseil | - |
Formation de Kathleen Glaub
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
22
Relations au 1er degré
13
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 13 |
|---|---|
Cell Genesys, Inc.
 Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Develops human disease therapies based on innovative gene modification technologies | Health Technology |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops medicines for cancer peoples | Health Technology |
Intel Corp.
 Intel Corp. SemiconductorsElectronic Technology Engages in design, development, manufacture and sale of CPUs and integrated circuits to computing and related end products | Electronic Technology |
Plexxikon, Inc.
Plexxikon, Inc. Miscellaneous Commercial ServicesCommercial Services Provides clinical and medical drug discovery and development services | Commercial Services |
Codexis, Inc.
 Codexis, Inc. Chemicals: SpecialtyProcess Industries Develops biocatalytic chemical processes | Process Industries |
Afferent Pharmaceuticals, Inc.
Afferent Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops novel, selective drugs for the treatment of a range of debilitating neurogenic disorders | Health Technology |
University of California, Berkeley
 University of California, Berkeley Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Kellogg School of Management
 Kellogg School of Management Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
IO Biotech ApS
IO Biotech ApS BiotechnologyHealth Technology Develops disruptive immune therapies | Health Technology |
CuraSen Therapeutics, Inc.
CuraSen Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company that develops novel treatments for psychiatric and neurodegenerative diseases | Health Technology |
Escient Pharmaceuticals, Inc.
 Escient Pharmaceuticals, Inc. BiotechnologyHealth Technology Operates as a drug discovery and development company | Health Technology |
Aligos Therapeutics, Inc.
 Aligos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops targeted, curative therapies for hepatologic diseases and viral infections | Health Technology |
IO Biotech, Inc.
 IO Biotech, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company that develops novel, immune-modulating cancer therapies | Health Technology |
